MeSH tree: D12.776.124.790.651.114.224.060
Early treatment of pediatric Crohn's disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas, a particularly debilitating complication of Crohn's disease.
Dec 23, 2024
0
20
A multi-institutional clinical trial led by the University of Navarra, Spain, found that blocking growth differentiation factor 15 (GDF-15) can counteract resistance to anti-PD-1 and anti-PD-L1 therapies in solid tumors.
A study led by Roswell Park Comprehensive Cancer Center provides new insight into the complex interactions of the "tumor-immune-gut axis," and its role in influencing immunotherapy responses in patients with recurrent ovarian ...
Dec 13, 2024
0
50
A significant advance in breast cancer research has uncovered a key mechanism driving cancer invasion and drug resistance. A University of Liverpool study reveals how two critical molecules present in "HER2-positive" breast ...
Dec 6, 2024
0
81
Results of a Phase III study conducted by an international team of researchers reveal that mirikizumab is more effective and has a favorable safety profile with fewer serious adverse events compared to a placebo for individuals ...
Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report. Smokers and drinkers, as well as those with HPV infections, are disproportionately affected.
Nov 22, 2024
0
26
For patients with chronic kidney disease (CKD), the risk for emergently treated hypocalcemia with denosumab increases with worsening CKD stage, according to a study published online Nov. 19 in the Annals of Internal Medicine.
Nov 20, 2024
0
16
A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a study by researchers from the Johns Hopkins Kimmel Cancer Center ...
Nov 14, 2024
0
17
The use of biologic and targeted therapies for children with juvenile idiopathic arthritis (JIA) surpassed more typical therapies in recent years, according to Rutgers Health researchers.
Nov 13, 2024
0
16
Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% of patients with stage 3 cutaneous melanoma, according to the results of a single-arm phase 2 clinical ...
Nov 1, 2024
0
39
